249 related articles for article (PubMed ID: 10325788)
81. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA.
Sontag MK; Wright D; Beebe J; Accurso FJ; Sagel SD
J Pediatr; 2009 Nov; 155(5):618-22. PubMed ID: 19540513
[TBL] [Abstract][Full Text] [Related]
82. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome.
Ren CL; Desai H; Platt M; Dixon M
Pediatr Pulmonol; 2011 Nov; 46(11):1079-84. PubMed ID: 21538969
[TBL] [Abstract][Full Text] [Related]
83. Sweat chloride and immunoreactive trypsinogen in infants carrying two
Castellani C; Tridello G; Tamanini A; Assael BM
Arch Dis Child; 2017 Jul; 102(7):644-646. PubMed ID: 26755536
[TBL] [Abstract][Full Text] [Related]
84. Newborn screening for cystic fibrosis in Serbia: a pilot study.
Radivojevic D; Sovtic A; Minic P; Grkovic S; Guc-Scekic M; Lalic T; Miskovic M
Pediatr Int; 2013 Apr; 55(2):181-4. PubMed ID: 23163630
[TBL] [Abstract][Full Text] [Related]
85. Outcome data from 15 years of cystic fibrosis newborn screening in a large UK region.
Driscoll SJ; Heinz K; Goddard P; Desai M; Gilchrist FJ
Arch Dis Child; 2024 Mar; 109(4):292-296. PubMed ID: 37973197
[TBL] [Abstract][Full Text] [Related]
86. Neonatal infection does not affect the immunoreactive trypsinogen screening test for cystic fibrosis.
Wilson DC; Leslie H; Edgar JD; Halliday HL; Dodge JA
J Pediatr Gastroenterol Nutr; 1994 Jul; 19(1):97-9. PubMed ID: 7965486
[TBL] [Abstract][Full Text] [Related]
87. Pilot study for cystic fibrosis neonatal screening: the Cuban experience.
Castells EM; Sánchez A; Frómeta A; Mokdse Y; Ozunas N; Licourt T; Arteaga AL; Silva E; Collazo T; Rodríguez F; Martín O; Espinosa M; Del Río L; Pérez PL; Morejón G; Almira C; Núñez Z; Melchor A; González EC
Clin Chem Lab Med; 2020 Oct; 58(11):1857-1864. PubMed ID: 32352395
[TBL] [Abstract][Full Text] [Related]
88. Neonatal cystic fibrosis screening: Analysis and differences in immunoreactive trypsin levels in newborns with a positive screen.
Arrudi-Moreno M; García-Romero R; Samper-Villagrasa P; Sánchez-Malo MJ; Martin-de-Vicente C
An Pediatr (Engl Ed); 2021 Jul; 95(1):11-17. PubMed ID: 34140271
[TBL] [Abstract][Full Text] [Related]
89. Diagnostic problems in cystic fibrosis - specific characteristics of a group of infants and young children diagnosed positive through neonatal screening, in whom cystic fibrosis had not been diagnosed.
Woś H; Sankiewicz-Szkółka M; Więcek S; Kordys-Darmolińska B; Grzybowska-Chlebowczyk U; Kniażewska M
Dev Period Med; 2015; 19(1):25-31. PubMed ID: 26003067
[TBL] [Abstract][Full Text] [Related]
90. The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis.
Dunn CT; Skrypek MM; Powers AL; Laguna TA
Pediatrics; 2011 Aug; 128(2):e446-9. PubMed ID: 21727111
[TBL] [Abstract][Full Text] [Related]
91. Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening.
Sontag MK; Corey M; Hokanson JE; Marshall JA; Sommer SS; Zerbe GO; Accurso FJ
J Pediatr; 2006 Nov; 149(5):650-657. PubMed ID: 17095337
[TBL] [Abstract][Full Text] [Related]
92. Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity.
Spence WC; Paulus-Thomas J; Orenstein DM; Naylor EW
Biochem Med Metab Biol; 1993 Apr; 49(2):200-11. PubMed ID: 7683477
[TBL] [Abstract][Full Text] [Related]
93. Newborn screening for cystic fibrosis in Victoria: 10 years' experience (1989-1998).
Massie RJ; Olsen M; Glazner J; Robertson CF; Francis I
Med J Aust; 2000 Jun; 172(12):584-7. PubMed ID: 10914103
[TBL] [Abstract][Full Text] [Related]
94. A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis.
Wells J; Rosenberg M; Hoffman G; Anstead M; Farrell PM
Pediatrics; 2012 Feb; 129(2):e339-47. PubMed ID: 22291119
[TBL] [Abstract][Full Text] [Related]
95. [Implementation of the neonatal cystic fibrosis screening program in Switzerland: beginning January 2011].
Mornand A; Barben J; Hafen G
Rev Med Suisse; 2011 Feb; 7(283):456, 458-60. PubMed ID: 21452515
[TBL] [Abstract][Full Text] [Related]
96. Retrospective study of the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Guthrie cards from a large cohort of neonatal screening for cystic fibrosis.
Verlingue C; Mercier B; Lecoq I; Audrézet MP; Laroche D; Travert G; Férec C
Hum Genet; 1994 Apr; 93(4):429-34. PubMed ID: 7513292
[TBL] [Abstract][Full Text] [Related]
97. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia.
Balnaves ME; Bonacquisto L; Francis I; Glazner J; Forrest S
J Med Genet; 1995 Jul; 32(7):537-42. PubMed ID: 7562966
[TBL] [Abstract][Full Text] [Related]
98. Comparison of two different protocols of neonatal screening for cystic fibrosis.
Narzi L; Lucarelli M; Lelli A; Grandoni F; Lo Cicero S; Ferraro A; Matarazzo P; Delaroche I; Quattrucci S; Strom R; Antonelli M
Clin Genet; 2002 Sep; 62(3):245-9. PubMed ID: 12220442
[TBL] [Abstract][Full Text] [Related]
99. Cystic fibrosis and neonatal screening.
Rodrigues R; Gabetta CS; Pedro KP; Valdetaro F; Fernandes MI; Magalhães PK; Januário JN; Maciel LM
Cad Saude Publica; 2008; 24 Suppl 4():s475-84. PubMed ID: 18797725
[TBL] [Abstract][Full Text] [Related]
100. Cystic fibrosis screening in neonates--measurement of immunoreactive trypsin and direct genotype analysis for delta F508 mutation.
Larsen J; Campbell S; Faragher EB; Götz M; Eichler I; Waldherr S; Dobianer K; Spona J
Eur J Pediatr; 1994 Aug; 153(8):569-73. PubMed ID: 7957403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
